Printer Friendly
The Free Library
19,573,962 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

APO Health Announces 23% Increase in Monthly Revenues.


Business Editors

OCEANSIDE, N.Y.--(BUSINESS WIRE)--Sept. 5, 2001

APO apo- 1 A prefix indicating a protein component in a conjugated molecule–eg, apoferritin, apolipoprotein, see there 2 Apolipoprotein, see there  Health (OTCBB OTCBB

See OTC Bulletin Board (OTCBB).
:APOA APOA Apolipoprotein A
APOA Albuquerque Police Officers Association
) realized revenue of $2.44 million (unaudited) in revenue during the month of August. This represents a 23% increase in revenue over July.

"August was a significant month for us. Coming out of a profitable third quarter, we are excited about continued growth going forward," states Dr. Jan Stahl, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  of APO Health.

About APO Health

APO Health is a multi-faceted distributor of medical, dental and veterinary supplies. These products include protective garments such as disposable isolation gowns, facemasks and gauzes as well as latex gloves, needles, syringes, pharmaceuticals, instruments, and health and beauty aids.

This press release contains forward-looking statements (within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995) that involve risks and uncertainties. A number of important factors could cause the Company's actual results, performance of achievements for fiscal 2001 and beyond to differ materially from that expressed in such forward-looking statements.

These factors are set forth in the Company's filings with the Securities and Exchange Commission and include, without limitation, material chances in economic conditions, competition in the Company's industry, operating losses, uncertainties relating to the developing market for new media, changing technologies, seasonality, ability to collect amounts owed to the Company, failure to accurately estimate the time and resources necessary for the performance of services, ability to maintain and expand name recognition, the Company's dependence on key clients and projects and key personnel, costs and uncertainties relating to closing offices, potential adverse effects of litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute.

When a person begins a civil lawsuit, the person enters into a process called litigation.
, and the ability of the Company to maintain the listing on the Over The Counter Bulletin Board stock exchange or another principal trading exchange.
COPYRIGHT 2001 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Sep 5, 2001
Words:280
Previous Article:Media Alert - R&B Singer Aaliyah's Tragic Death Stirs Online Interest, Pushing the Pop Star to Top of the List; Britney Spears Falls to Her Lowest...
Next Article:Computerworld Salary Survey Finds Increase in Technology Salaries Outstrips National Average.
Topics:



Related Articles
Alcohol and the heart.
Artery clogging and APO-B.
Apo E in Alzheimer's stunts nerve growth.
Apo E: caught inside the nerve cell.
One team, two clues in Alzheimer's puzzle.
NEHA's Shipping and Handling Charges.
NEHA Shipping Polity Changes.
Consider the hazelnut as a nutritional source.
Foodborne disease: a focus for health education.
Cardiovascular effects of pulmonary exposure to single-wall carbon nanotubes.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles